中文摘要：

目的观察护心康片治疗气虚痰瘀互阻型不稳定型心绞痛（UAP）的临床疗效及对同型半胱氨酸（Hcy）和高敏C反应蛋白（Hs-CRP）的影响。方法将65例患者随机分为对照组32例和观察组33例。两组均给予常规西药治疗,对照组加服通心络胶囊,而观察组加服护心康片,疗程1个月。观察两组的临床疗效、心绞痛疗效、心电图疗效和中医证候疗效及治疗前后血脂、Hcy和Hs-CRP等指标的变化。结果两组间临床疗效、心绞痛疗效、心电图疗效及中医证候疗效差异有统计学意义（P〈0.05）;两组治疗前后血脂、Hcy和Hs-CRP差异均有统计学意义（P〈0.05）,组间比较观察组优于对照组（P〈0.05）。结论护心康片治疗气虚痰瘀互阻型UAP具有较好的临床疗效,能有效改善血脂代谢功能及抑制Hcy和Hs-CRP水平。

英文摘要：

Objective To observe the clinical effect of Huxinkang tablet on unstable angina pectoris （UAP） with the syndrome of Qi deficiency and phlegm and blood stasis （QDPBS） and its effect on the homocysteine （Hcy） and high sensitivity C-reactive protein （Hs-CRP）. Methods 65 patients were randomly divided into the control group （32 cases） and observation group （33 cases）. All patients were firstly treated with the western medicine therapy. Then, patients in the control group are administered Tongxinluo Capsules, while patients in the observation group were administered Huxinkang tablet for one month. The clinical effect and curative effect of the angina pectoris （AP）, electrocardiograph （ECG） and Chinese medicine syndrome （CMS） are observed after the treatment, as well as the change of the indices of the blood fat, Hcy and Hs-CRP before, and after the treatment. Results The clinical effect and the curative effects of the AP, ECG and CMS between the two groups are statistically significant （P〈0.05）. The blood fat, Hey and Hs-CRP in both groups before and after treatment are statistically significant （P〈0.05）, but these indices of the treatment group are superior to these of the control group （P〈0.05）. Conclusion Huxinkang tablet showed good effect on the treatment of UAP with the syndrome of QDPBS. It can improve the lipid metabolism function and inhibit the levels of the Hey and Hs-CRP.